Literature DB >> 18438736

Specific single chain variable fragment (ScFv) antibodies to angiotensin II AT(2) receptor: evaluation of the angiotensin II receptor expression in normal and tumor-bearing mouse lung.

Masaaki Tamura1, Heping Yan, Ofelia Zegarra-Moro, Jennifer Edl, Stephanie Oursler, Cindy Chard-Bergstrom, Gordon Andrews, Tsutomu Kanehira, Susumu Takekoshi, Ray Mernaugh.   

Abstract

To gain insight into the mechanism by which angiotensin II type 2 receptor (AT(2)) regulates carcinogen-induced lung tumorigenesis, we have newly developed anti-AT(2) single chain variable fragment (ScFv) antibodies using a rodent phage-displayed recombinant antibody library with various peptide fragments of the receptor protein, and investigated the expression of the AT(2) receptor protein. The specificity of the antibodies was verified using AT(2) over-expressing COS-7 cells and AT(2) naturally expressing PC12W cells. In control wild type mouse lung, a stronger immunoreactivity was observed in bronchial epithelial cells. A moderate immunoreactivity was detected in pulmonary vascular walls and vascular endothelial cells. In the lungs possessing tobacco-specific nitrosamine (NNK)-induced tumors, significantly increased AT(2) and AT(1 )immunostaining was observed in adenomatous lesions. These data suggest that the increase in both receptors' expression in the alveolar epithelial cells may be accompanied with the onset of NNK-induced tumorigenesis and hence play important roles in lung tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18438736      PMCID: PMC2914475          DOI: 10.1007/s10735-008-9172-3

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  36 in total

1.  Therapeutic expression of an anti-death receptor 5 single-chain fixed-variable region prevents tumor growth in mice.

Authors:  Juan Shi; Yanxin Liu; Yong Zheng; Yabin Guo; Jinchun Zhang; Pik-To Cheung; Ruian Xu; Dexian Zheng
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

Review 2.  Physiological and pharmacological implications of AT1 versus AT2 receptors.

Authors:  O Chung; H Kühl; M Stoll; T Unger
Journal:  Kidney Int Suppl       Date:  1998-09       Impact factor: 10.545

3.  Differential inducibility of angiotensin II AT2 receptor between SHR and WKY vascular smooth muscle cells.

Authors:  T Ichiki; Y Kambayashi; T Inagami
Journal:  Kidney Int Suppl       Date:  1996-06       Impact factor: 10.545

4.  Pivotal role of tyrosine phosphatase SHP-1 in AT2 receptor-mediated apoptosis in rat fetal vascular smooth muscle cell.

Authors:  T Cui; H Nakagami; M Iwai; Y Takeda; T Shiuchi; L Daviet; C Nahmias; M Horiuchi
Journal:  Cardiovasc Res       Date:  2001-03       Impact factor: 10.787

5.  Angiotensin II type 2 receptor gene deficiency attenuates susceptibility to tobacco-specific nitrosamine-induced lung tumorigenesis: involvement of transforming growth factor-beta-dependent cell growth attenuation.

Authors:  Tsutomu Kanehira; Tatsuo Tani; Tetsuo Takagi; Yuichirou Nakano; Eric F Howard; Masaaki Tamura
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

Review 6.  Angiotensin II receptors and angiotensin II receptor antagonists.

Authors:  P B Timmermans; P C Wong; A T Chiu; W F Herblin; P Benfield; D J Carini; R J Lee; R R Wexler; J A Saye; R D Smith
Journal:  Pharmacol Rev       Date:  1993-06       Impact factor: 25.468

Review 7.  Extrarenal aspects of angiotensin II function.

Authors:  T Csikós; S Gallinat; T Unger
Journal:  Eur J Endocrinol       Date:  1997-04       Impact factor: 6.664

8.  Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide.

Authors:  S Dimmeler; V Rippmann; U Weiland; J Haendeler; A M Zeiher
Journal:  Circ Res       Date:  1997-12       Impact factor: 17.367

Review 9.  Recent progress in angiotensin II type 2 receptor research in the cardiovascular system.

Authors:  M Horiuchi; M Akishita; V J Dzau
Journal:  Hypertension       Date:  1999-02       Impact factor: 10.190

10.  The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells.

Authors:  M Stoll; U M Steckelings; M Paul; S P Bottari; R Metzger; T Unger
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

View more
  6 in total

1.  Small molecular peptide-ScFv αvβ3 conjugates specifically inhibit lung cancer cell growth in vitro and in vivo.

Authors:  Qianqian Qiu; Qiongyao Wang; Changxu Deng; Yanqin Sun; Taoliang Chen; Linlang Guo; Fan Zhang
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

2.  Over-expression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells.

Authors:  Lara Pickel; Takaya Matsuzuka; Chiyo Doi; Rie Ayuzawa; Dharmendra Kumar Maurya; Sheng-Xue Xie; Cory Berkland; Masaaki Tamura
Journal:  Cancer Biol Ther       Date:  2009-12-22       Impact factor: 4.742

3.  Characterization of the native and denatured herceptin by enzyme linked immunosorbent assay and quartz crystal microbalance using a high-affinity single chain fragment variable recombinant antibody.

Authors:  Yuqin Shang; Ray Mernaugh; Xiangqun Zeng
Journal:  Anal Chem       Date:  2012-09-13       Impact factor: 6.986

Review 4.  Angiotensin peptides and lung cancer.

Authors:  Patricia E Gallagher; Katherine Cook; David Soto-Pantoja; Jyotsana Menon; E Ann Tallant
Journal:  Curr Cancer Drug Targets       Date:  2011-05       Impact factor: 3.428

5.  Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?

Authors:  T Dolley-Hitze; F Jouan; B Martin; S Mottier; J Edeline; O Moranne; P Le Pogamp; M-A Belaud-Rotureau; J-J Patard; N Rioux-Leclercq; C Vigneau
Journal:  Br J Cancer       Date:  2010-11-23       Impact factor: 7.640

6.  Renin-Angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib.

Authors:  Adnan Aydiner; Rumeysa Ciftci; Fatma Sen
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.